A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/22/2011	WO2011158248A2 Process for preparation of posaconazole and crystalline polymorphic form v of posaconazole
12/22/2011	WO2011158206A1 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
12/22/2011	WO2011158197A1 New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions
12/22/2011	WO2011158178A1 Use of dronedarone for the preparation of a medicament for use in the treatment of patients
12/22/2011	WO2011158176A2 Gold complexes
12/22/2011	WO2011158175A2 Polyphenol derivative composition and uses thereof as bactericide and fungicide
12/22/2011	WO2011158149A1 2-(3,5-disubstitutedphenyl)pyrimidin-4(3h)-one derivatives
12/22/2011	WO2011158058A1 α-CRYSTALLINE FORM OF CARBABENZPYRIDE
12/22/2011	WO2011158053A1 Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
12/22/2011	WO2011158052A1 Nanostructured ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them
12/22/2011	WO2011158050A1 Process for the preparation of dronedarone
12/22/2011	WO2011158044A2 Respiratory formulations and compounds for use therein
12/22/2011	WO2011157968A1 Cosmetic use of arabinoxylan-oligosaccharides
12/22/2011	WO2011157936A1 Compositions containing flavones and anthelmintics
12/22/2011	WO2011157908A1 Use of the combination of an inhibitor of the if current of the sinoatrial node and an inhibitor of the angiotensin-converting enzyme for treating heart failure
12/22/2011	WO2011157880A1 Antioxidant composition
12/22/2011	WO2011157827A1 Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
12/22/2011	WO2011157798A1 Methods and compositions for stimulating reepithelialisation during wound healing
12/22/2011	WO2011157793A1 Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
12/22/2011	WO2011157787A1 Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
12/22/2011	WO2011157743A1 Alpha-crystalline form of carbabenzpyride
12/22/2011	WO2011157730A1 Process for the preparation of controlled release tablet
12/22/2011	WO2011157722A2 Solid ivabradine-containing composition
12/22/2011	WO2011157721A2 Ivabradine-containing pharmaceutical composition
12/22/2011	WO2011157720A2 Ivabradine-containing pharmaceutical composition with modified release
12/22/2011	WO2011157719A1 An injectable dosage form of flupirtine
12/22/2011	WO2011157688A1 Substituted triazolopyridines
12/22/2011	WO2011157682A1 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators
12/22/2011	WO2011157664A1 Process for preparing tetrazole-substituted anthranilamide derivatives and novel crystal polymorph of these derivatives
12/22/2011	WO2011157642A1 Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
12/22/2011	WO2011157536A1 Process for the preparation of glycopyrronium chloride
12/22/2011	WO2011157450A1 New polymorphic form of imatinib base and preparation of salts thereof
12/22/2011	WO2011157449A1 Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives
12/22/2011	WO2011157443A1 (11b,17a)-11-(4-(2-11c-acetyl)phenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one
12/22/2011	WO2011157428A2 In-situ lecithin microemulsion gel formulation
12/22/2011	WO2011157416A2 Transdermal administration of memantine
12/22/2011	WO2011157397A1 Heteroaryl imidazolone derivatives as jak inhibitors
12/22/2011	WO2011157391A1 Pharmaceutical combination for the treatment of pain
12/22/2011	WO2011157387A1 Crystal form of glycopyrronium chloride
12/22/2011	WO2011157294A1 Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
12/22/2011	WO2011157227A1 Compounds having activating effect on subtypes of peroxisome proliferator-activated receptors and its preparation method and uses
12/22/2011	WO2011157059A1 Use of isoacteoside or pharmaceutically acceptable saltthereof
12/22/2011	WO2011156970A1 Uses of mtea in diagnosis and treatment of malignant tumor
12/22/2011	WO2011156908A1 Methods of treating or preventing estrogen-related diseases
12/22/2011	WO2011156889A1 Novel modulators of nrf2 and uses thereof
12/22/2011	WO2011142795A9 Novel analogs of curcumin and methods of use
12/22/2011	WO2011140644A8 Polyacetal or polyketal and ether polymers
12/22/2011	WO2011139348A9 Uses of phospholipid conjugates of synthetic tlr7 agonists
12/22/2011	WO2011135332A3 Nmn modulators for the treatment of neurodegenerative disorders
12/22/2011	WO2011134444A3 Substitution derivatives of n6-benzyladenosine-5´-monophosphate, methods of preparation thereof, use thereof as medicaments, and therapeutic preparations containing these compounds
12/22/2011	WO2011131368A3 A method of preparing an oral dosage form comprising fingolimod
12/22/2011	WO2011128434A3 Treatment of endocrine resistant breast cancer
12/22/2011	WO2011119345A3 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
12/22/2011	WO2011119247A3 Topical skincare composition
12/22/2011	WO2011112825A3 Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
12/22/2011	WO2011112689A9 Salts of an indazolylpyrrolotriazine
12/22/2011	WO2011112535A3 Propionic acids, propionic acid esters, and related compounds
12/22/2011	WO2011108006A3 A novel liquid oral spray dosage form comprising thiocolchicoside and anti-inflammatory agent
12/22/2011	WO2011100671A3 Methods and compositions to improve mechanical resistance of teeth
12/22/2011	WO2011100659A3 Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
12/22/2011	WO2011100543A9 Methods of reducing or inhibiting toxic effects associated with a bacterial infection using alkaline phosphatase
12/22/2011	WO2011097594A3 Therapeutic methods and compositions involving allosteric kinase inhibition
12/22/2011	WO2011097577A9 Compositions and methods for treating or preventing retinal degeneration
12/22/2011	WO2011097347A3 Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
12/22/2011	WO2011097327A3 Compositions and methods of modulating receptor protein tyrosine phosphatases
12/22/2011	WO2011095985A3 Rasagiline salts and processes for the preparation thereof
12/22/2011	WO2011094671A3 N-terminally conjugated polypeptides for targeted therapy and diagnosis
12/22/2011	WO2011093825A3 Effervescent dosage forms comprising cephalosporin antibiotic
12/22/2011	WO2011093824A3 Effervescent formulations comprising cefaclor
12/22/2011	WO2011091131A3 Eslicarbazepine acetate and its polymorphs
12/22/2011	WO2011089531A3 Effects of the association of vitamin k2 and vitamin d3 in the consolidation of a bone fracture
12/22/2011	WO2011088219A3 Therapeutics and processes for treatment of immune disorders
12/22/2011	WO2011086575A8 A pharmaceutical composition for treatment of respiratory tract infections
12/22/2011	WO2011085351A9 Method of treating kcnq related disorders
12/22/2011	WO2011050947A8 Tape, in particular, adhesive tape, for the treatment of skin disorders comprising at least one hyperkeratosis inhibitor and/or at least one keratinolytic agent
12/22/2011	WO2011012816A3 Pharmaceutical formulation
12/22/2011	WO2011005646A3 Pharmaceutical composition for a hepatitis c viral protease inhibitor
12/22/2011	WO2010139967A8 Dihydroindole and tetrahydroisoquinoline derivatives useful as potassium channel inhibitors
12/22/2011	WO2010136594A3 Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
12/22/2011	WO2010130983A8 A method and composition for the control of ectoparasites
12/22/2011	WO2010111891A8 Modified oligo-nucleic acid molecule, preparation method and uses thereof
12/22/2011	WO2008068638A8 Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
12/22/2011	US20110313372 Transdermal administration of memantine
12/22/2011	US20110313233 Down-regulation of cold shock proteins for cancer treatment
12/22/2011	US20110313229 Therapy Targeting Cancer Stem Cells
12/22/2011	US20110313051 Delivery system for topical medications
12/22/2011	US20110313050 Solid composition containing the ingredient rasagiline
12/22/2011	US20110313049 Antibacterial compositions comprising quaternary ammonium germicides and alkamine oxides having reduced irritation potential
12/22/2011	US20110313048 Antimicrobial silicone-based wound dressings
12/22/2011	US20110313046 Combination therapy with lisdexamphetamine and extended release guanfacine
12/22/2011	US20110313045 Histone deacetylases, and uses related thereto
12/22/2011	US20110313044 Polymorphs of Suberoylanilide Hydroxamic Acid
12/22/2011	US20110313043 Amino Acid Compositions
12/22/2011	US20110313042 Amino Acid Compositions
12/22/2011	US20110313041 Food supplements on the basis of pantothenic acid
12/22/2011	US20110313040 Organic nutrient salts, methods of preparation and uses
12/22/2011	US20110313039 Method for increasing endogenous plasmalogen levels in mammals
12/22/2011	US20110313038 Cationic oil-in-water emulsions containing prostaglandins and uses thereof
12/22/2011	US20110313037 [2.2.2] Bicyclic Derivatives and Methods of Use
12/22/2011	US20110313036 CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG

1 ... 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 ... 7860